Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 88

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 88
---
 A$4,851,839 to nil), partially offset by an increase in cash receipts from customers
(from A$260,462 to A$5,353,973), an increase in cash received from interest income (from A$50,484 to A$800,309)

Investing Activities

Net cash used in investing
activities increased from a payment of A$320,000 in fiscal 2024 to proceeds of A$1,770,598 in fiscal 2025, due to an increase in cash
received from payments for intellectual property (from nil to A$2,997,592) and an increase of payments for license fee liabilities (A$320,000
to A$1,226,994).

Financing Activities

Net cash received from financing
activities increased from A$30,196,945 in fiscal 2024 to A$45,431,548 in fiscal 2025, due to an increase in the proceeds received from
the issuance of equity securities (from A$29,645,526 to A$53,977,902), partially offset by an increase in the transaction costs related
to share issuances (from A$1,533,771 to A$4,738,000), an increase in the costs related to loans and borrowings (from A$117,000 to A$218,633),
an decrease in repayment of borrowings (from A$5,167,000 to A$1,900,000 and a decrease in the proceeds received from borrowings (from
A$7,369,190 to nil)).

Comparison of cash flows for the fiscal year ended June 30, 2024,
with June 30, 2023

The following table summarizes our cash flows for
the periods presented:

                                                 Year ended June 30,                                              
                                                 2024                                      2023                   
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                 A$                                        A$                     
  Net cash used in operating activities                                   (22,975,935                (23,201,798  
  Net cash used in investing activities                                      (320,000                 (1,530,681  
  Net cash provided by financing activities                                30,196,945                  9,217,791  

Operating Activities

Net cash used in operating
activities decreased from A$23,201,798 in fiscal 2023 to A$22,975,935 in fiscal 2024,